Physician profile
Howard S Blank
NPI 1699787424
$823.74
in general payments reported to CMS, 2019-2025
14 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.07 · 2020: $43.40 · 2021: $52.27 · 2022: $103 · 2023: $105 · 2024: $210 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $177.81 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $174.43 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $81.33 | 2019-2025 | Evenity, Tepezza |
| Insulet Corporation | $74.67 | 2024-2025 | Omnipod |
| Pfizer INC. | $69.71 | 2019-2024 | |
| Medtronic, INC. | $60.58 | 2022-2024 | Minimed 780g |
| Sequel Med Tech, LLC | $41.22 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $39.09 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $24.95 | 2023 | Isturisa, Signifor Lar |
| Sanofi-Aventis U.S. LLC | $19.43 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $18.38 | 2024 | |
| Horizon Therapeutics Plc | $16.38 | 2020 | |
| Medtronic Minimed, INC. | $13.77 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Blank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.